Atika Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Atika Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,000	Closed	-$6.09M	–	118
2024 Q2	$6.09M	Buy	+13,000	New	+$5.64M	0.6%	56
2020 Q2	–	Sell	-8,000	Closed	-$1.9M	–	117
2020 Q1	$1.9M	Buy	+8,000	New	+$1.84M	0.36%	68
2019 Q2	–	Sell	-26,000	Closed	-$4.78M	–	95
2019 Q1	$4.78M	Buy	26,000 +5,500	+27%	+$1.02M	0.97%	44
2018 Q4	$3.4M	Buy	20,500 +2,500	+14%	+$433K	1%	40
2018 Q3	$3.47M	Buy	18,000 +6,000	+50%	+$1.07M	0.62%	62
2018 Q2	$2.04M	Sell	12,000 -3,000	-20%	-$465K	0.39%	76
2018 Q1	$2.44M	Buy	15,000 +3,000	+25%	+$490K	0.84%	46
2017 Q4	$1.8M	Buy	+12,000	New	+$1.78M	0.7%	55
2015 Q1	–	Sell	-9,500	Closed	-$1.13M	–	77
2014 Q4	$1.13M	Sell	9,500 -15,000	-61%	-$1.69M	0.83%	47
2014 Q3	$2.75M	Buy	+24,500	New	+$2.33M	2.12%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atika Capital Management's VRTX Position: Q3 2024 in Review

Atika Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 13,000 shares — an estimated $6.09M sold.

Atika Capital Management first reported a position in VRTX in Q3 2014 and held it in 10 quarters. The position peaked at $6.09M in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Atika Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Atika Capital Management sold 13,000 Vertex Pharmaceuticals shares in Q3 2024, an estimated $6.09M.
Atika Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Atika Capital Management's Vertex Pharmaceuticals position peaked at $6.09M in Q2 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Atika Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.